Trials / Recruiting
RecruitingNCT07260812
KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
A Phase I Clinical Study on the Safety, Tolerability, and Efficacy of KSV01 Injection in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- TCRx Therapeutics Co.Ltd · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KSV01 Injection for patients with diffuse large B-cell lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KSV01 Injection | KSV01 Injection is one kind of third-generation non-replicative self-inactivating lentivirus vector which carries CD19 CAR. |
Timeline
- Start date
- 2025-09-01
- Primary completion
- 2028-12-31
- Completion
- 2028-12-31
- First posted
- 2025-12-03
- Last updated
- 2026-04-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07260812. Inclusion in this directory is not an endorsement.